NCT04553133 2026-04-13
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
Pfizer
NRG Oncology
Hoffmann-La Roche
Eli Lilly and Company
OHSU Knight Cancer Institute
Jonsson Comprehensive Cancer Center
Dana-Farber Cancer Institute